Moderna admits here that what they inject now is an “operating system.”

Moderna is coming for six month old babies..
It is now apparent that Moderna had already completed development of its mRNA gene therapy shot in 2019 BEFORE COVID-19 was announced to be spreading from China to the world. This has serious ramifications to the entire pandemic narrative.

There are only two possibilities. First, Moderna had advance knowledge of the COVID-19 virus and created a shot to prepare for it. Second, Moderna didn’t have advance knowledge but was developing a generic gene therapy treatment that could be directed toward any type of coronavirus. Either possibility is disturbing. ⁃ TN Editor..https://www.technocracy.news/mercola-moderna-had-specific-covid-19-mrna-shot-ready-in-2019-before-pandemic-was-announced/

Enabling Drug Discovery & Development
We built Moderna on the guiding premise that if using mRNA as a medicine works for one disease, it should work for many diseases. And, if this is possible – given the right approach and infrastructure – it could meaningfully improve how medicines are discovered, developed and manufactured.

Our Operating System

Recognizing the broad potential of mRNA science, we set out to create an mRNA technology platform that functions very much like an operating system on a computer. It is designed so that it can plug and play interchangeably with different programs. In our case, the “program” or “app” is our mRNA drug – the unique mRNA sequence that codes for a protein.
We have a dedicated team of several hundred scientists and engineers solely focused on advancing Moderna’s platform technology. They are organized around key disciplines and work in an integrated fashion to advance knowledge surrounding mRNA science and solve for challenges that are unique to mRNA drug development. Some of these disciplines include mRNA biology, chemistry, formulation & delivery, bioinformatics and protein engineering.

Our mRNA Medicines – The ‘Software of Life’
When we have a concept for a new mRNA medicine and begin research, fundamental components are already in place.
Generally, the only thing that changes from one potential mRNA medicine to another is the coding region – the actual genetic code that instructs ribosomes to make protein. Utilizing these instruction sets gives our investigational mRNA medicines a software-like quality. We also have the ability to combine different mRNA sequences encoding for different proteins in a single mRNA investigational medicine.
We are leveraging the flexibility afforded by our platform and the fundamental role mRNA plays in protein synthesis to pursue mRNA medicines for a broad spectrum of diseases.
Within a given modality, the base components are generally identical across development candidates – formulation, 5’ region and 3’ region. Only the coding region varies based on the protein/s the potential medicine is directing cells to produce.
https://tapnewswire.com/2021/01/moderna-admits-here-that-what-they-inject-now-is-an-operating-system/